Market Overview

The pneumococcal vaccine market was valued at USD 9.16 billion in 2025 and is estimated at USD 9.61 billion in 2026. It is projected to reach USD 14.57 billion by 2034, expanding at a CAGR of 5.30% from 2026 to 2034. Pneumococcal vaccines are immunization products that protect against infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, bacteremia and otitis media. They are widely used in pediatric and adult programs to reduce disease burden, hospitalizations and mortality. Vaccination is advisable for infants, people over 65 and those with chronic diseases or weak immune systems. Growth is supported by rising cases of pneumococcal disease across all age groups and by health policies that promote widespread vaccination.

Vaccine Type and Product Segments

By vaccine type, the pneumococcal polysaccharide vaccine segment led with a 54.6% revenue share in 2025, owing to its broad coverage of multiple strains and established use in preventing serious infections among adults, particularly those with underlying health conditions. The pneumococcal conjugate vaccine segment is expected to register the highest CAGR of 7.2%, as these products improve and retain immunity better than polysaccharide options and cover a wider range of Streptococcus pneumoniae. The report adds that conjugate products develop durable immune memory and are routinely recommended for children, while polysaccharide vaccines are used primarily in older and high-risk adults.

By product, Synflorix is expected to record the highest CAGR of 7.6% because of its cost-effectiveness, which makes it popular in countries with budget constraints. Prevnar 13 benefits from wide global availability and approvals covering infants, children and adults. The report's product categories also include Pneumovax23 and others, and end users are divided into public and private sectors.

Pediatric and Adult Demand

Childhood immunization remains the cornerstone of the market. The World Health Organization estimates that pneumococcal disease causes roughly 1.6 million deaths each year, of which 0.7 to 1 million occur in children under five. In 2022, GAVI reported that coverage of the third PCV dose rose to 70% across its 57 member countries, up from 56% in 2019-2021. The Odisha government introduced PCV in June 2021 to protect 800,000 young children.

Adult vaccination is becoming a second growth driver as populations age and guidelines change. The CDC's Advisory Committee on Immunization Practices has expanded PCV coverage by lowering the recommended age from 65 to 50 years, and adults with conditions such as COPD, diabetes and heart disease face a higher risk of pneumonia. In June 2021, Pfizer announced that the U.S. FDA had approved Prevnar 20 for adults aged 18 and older to prevent invasive pneumococcal disease and pneumonia.

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market 

Regional Insights and Restraints

North America dominated in 2025 with a 40.9% share, supported by strong healthcare infrastructure, early vaccine adoption, a growing number of FDA approvals and a strong network of major pharmaceutical companies that drive innovation. Asia Pacific is projected to register the highest CAGR of 6.8%, driven by investment in vaccine development, a rapidly expanding population and a rising incidence of pneumococcal infections. In September 2022, Indonesia launched PCV nationwide to improve access for children at the lowest price.

Stringent rules and lengthy approval processes for new vaccines can discourage investors and slow development. The market is fragmented, and growing R&D investment, together with cost reductions in PCV and vaccine development in middle-income countries, is expected to support growth.

Key Players

• GSK plc
• Pfizer Inc.
• Merck KGaA
• Serum Institute of India Pvt. Ltd.
• CSL Ltd.
• Sanofi S.A.
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd
• Johnson & Johnson
• AstraZeneca
• Novavax

Conclusion

The pneumococcal vaccine market combines steady public health demand with an active innovation pipeline. North America's leadership, Asia Pacific's faster growth and the rising importance of both pediatric and older-adult protection give manufacturers, distributors and policymakers clear priorities. Stakeholders that align product portfolios with cost-sensitive markets, broader age groups and evolving guidelines will be well placed to capture opportunities through 2034.

More Trending Latest Reports By Polaris Market Research:

Heated Jacket Market

Attention Deficit Hyperactivity Disorder Market

Chocolate Syrup Market

Aerospace Coatings Market

North America Crop Protection Chemicals Market

COVID-19 Sample Collection Kits Market

COVID-19 Sample Collection Kits Market

Chocolate Syrup Market

Metal Cans Market